Patents by Inventor Bitao LIANG

Bitao LIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T lymphocyte production methods and t lymphocytes produced thereby
    Patent number: 11834675
    Abstract: Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation. Also provided herein are methods of using said cytotoxic T lymphocytes, for example, to treat cancer and/or viral infection.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: December 5, 2023
    Assignee: CELGENE CORPORATION
    Inventors: Bitao Liang, Xiaohua Lu, Wei Liu, Kathy E. Karasciewicz-Mendez, Christopher Wiwi, Kruti Shah
  • Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
    Patent number: 11806365
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: November 7, 2023
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Methods of improving vector transduction efficiency into T lymphocytes
    Patent number: 11629335
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: April 18, 2023
    Assignee: CELGENE CORPORATION
    Inventors: Bitao Liang, Wei Liu
  • CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20220106404
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Application
    Filed: September 10, 2021
    Publication date: April 7, 2022
    Inventors: Stewart ABBOT, Bitao LIANG, Tianjian LI
  • METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES
    Publication number: 20210309966
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 7, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Wei LIU
  • MODIFIED T LYMPHOCYTES
    Publication number: 20210299175
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 30, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Chimeric antigen receptors
    Patent number: 11130820
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 28, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT
    Publication number: 20210254003
    Abstract: In one embodiment, provided herein are cells, e.g., T cells expressing receptors that that cause a cell expressing the receptors to home to specific anatomical regions, e.g., the B cell zone of lymph nodes, the gastrointestinal tract, or the skin. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: August 19, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Wei LIU, Tianjian LI
  • T LYMPHOCYTE PRODUCTION METHODS AND T LYMPHOCYTES PRODUCED THEREBY
    Publication number: 20210163890
    Abstract: Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation. Also provided herein are methods of using said cytotoxic T lymphocytes, for example, to treat cancer and/or viral infection.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 3, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Xiaohua LU, Wei LIU, Kathy E. KARASCIEWICZ-MENDEZ, Christopher WIWI, Kruti SHAH
  • Methods of improving vector transduction efficiency into T lymphocytes
    Patent number: 10982189
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 20, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Bitao Liang, Wei Liu
  • Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
    Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • MODIFIED T LYMPHOCYTES
    Publication number: 20190175652
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 13, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190119399
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Application
    Filed: October 30, 2018
    Publication date: April 25, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
    Patent number: 10238690
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 26, 2019
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Chimeric antigen receptors
    Patent number: 10150816
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: December 11, 2018
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY
    Publication number: 20180273640
    Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Bitao Liang, Stewart Abbot, Wei Liu
  • CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT
    Publication number: 20180080008
    Abstract: In one embodiment, provided herein are cells, e.g., T cells expressing receptors that that cause a cell expressing the receptors to home to specific anatomical regions, e.g., the B cell zone of lymph nodes, the gastrointestinal tract, or the skin. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: August 11, 2015
    Publication date: March 22, 2018
    Applicant: Anthrogenesis Corporation
    Inventors: Bitao LIANG, Wei LIU, Tianjian LI
  • METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES
    Publication number: 20170166866
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 15, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Bitao LIANG, Wei LIU
  • MODIFIED T LYMPHOCYTES
    Publication number: 20160030479
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY
    Publication number: 20150368360
    Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.
    Type: Application
    Filed: February 6, 2014
    Publication date: December 24, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Bitao Liang, Stewart Abbot, Wei Liu